We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ISAC

News List

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody ISAC Programs firstwordpharma
August 27, 2021
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, and Innovent Biologics.
Genmab, Bolt ink deal to develop bispecific immune-stimulating antibody conjugates firstwordpharma
June 03, 2021
Genmab entered into an agreement with Bolt Biotherapeutics to develop next-generation, immune-stimulatory, antibody-based conjugate therapeutics for the treatment of cancer, the companies announced Wednesday.